Event calendar

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Oral Session Title: ART Offspring           

Monday, October 14, 2019        10:45 am-12:15 pm Eastern Daylight Time (EDT)

Abstract O-16 – 11:30 AM EDT: “Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal And Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial.”

Poster Presentation Session Topic: Endometriosis

Wednesday, October 16, 2019  6.30am-7.45am Eastern Daylight Time (EDT)

Abstract P-539: “Long Term Treatment of Endometriosis Associated Pain (EAP) with Linzagolix: Efficacy and Safety after 12 Months of Treatment.”

ObsEva will also be at Booth # 1005 of the exhibition hall.

Are you sure you want to leave ObsEva.com?

We're sorry to see you go.
Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue